mesalazine信息详情
美沙拉秦
Objective: To investigate the stability of Mesalazine enter-coated tablets in different media.───目的：考察美沙拉嗪肠溶片在不同介质中的稳定性。
Objective:To establish a method for quality control of Mesalazine enteric coated tablet.───目的：制定美沙拉嗪肠溶片的质量标准方法。
Mesalazine was a new anti-ulcerous colitis drug.───美沙拉秦是一种新型抗溃疡性结肠炎药物。
Determination of Related Substances in Mesalazine by HPLC-Electrochemical Detection───美沙拉秦中有关物质的HPLC-电化学检测法测定
Synthesis and Structural Identification of Anti-colitis Drug Mesalazine───抗结肠炎药美沙拉嗪的合成及结构鉴定
Spectral data analysis and structure identification of mesalazine───美沙拉秦的波谱学数据与结构表征
Process Research of Heavy Nitrogen Reaction and Extraction in Production of Mesalazine───美沙拉嗪生产过程中重氮反应及萃取过程的工艺研究
Determination of mesalazine enter-coated tablets by convolution curve───美沙拉嗪肠溶片的褶合光谱法测定
Clinical effect of mesalazine in the treatment of ulcerative colitis───美沙拉秦治疗溃疡性结肠炎疗效观察
After oral administration, mesalazine is extensively acetylated such that N-acetyl-5-ASA is the predominant form found in both plasma and urine.
Studies of the effect of mesalazine on renal function are relatively few.
Delayed release mesalazine formulations release their contents rapidly in the distal small intestine and proximal colon.
Furthermore, no correlations were found between measures of renal function and either cumulative mesalazine dose or mesalazine treatment duration.
In the rat, very high single doses of intravenous mesalazine cause acute tubular and papillary necrosis.
Objective:To observe the efficacy and safety of Etiasa, a control released tablet of mesalazine, in treatment of inflammatory bowel disease(IBD) in comparison with salicylazosulfapyridine (SASP).
No significant correlations were apparent between creatinine clearance and either duration of mesalazine treatment or cumulative mesalazine dose.
Plasma concentrations of 5-ASA may therefore be higher in patients taking delayed release mesalazine than in patients taking equivalent doses of sulphasalazine.